Australia Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore

Australia Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore

  • May 2017 •
  • 220 pages •
  • Report ID: 4895090 •
  • Format: PDF

Uterine fibroid embolization (UFE), also known as uterine artery embolization (UAE) is a radiology treatment for fibroids.

Fibroids, also known as myomas, are masses of muscle tissue and fiber located on the wall of the uterus that can cause heavy bleeding and pain. Fibroids depend on the uterine arteries for nourishment, and they take significant blood supply from these vessels. UFE restricts blood flow to fibroids, causing them to shrink significantly.

This procedure does not involve general anesthesia and is appropriate for women who want an alternative to a myomectomy, also known as fibroidectomy. It is a much less invasive way to treat fibroids than a hysterectomy, has a much shorter recovery time and leaves almost no scarring. The effects of UFE on fertility are being researched; some results suggest that fertility after UFE is comparable to fertility after myomectomy.

Description
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions

The UFE market has decreased in growth in part because of a reduction in active marketing. Moreover, UFE must compete with a wide array of procedures available to treat heavy bleeding due to uterine fibroids. These other treatments and procedures include hysterectomy, pharmacological alternatives, global endometrial ablation, endometrial resection and other minimally invasive surgical procedures. The complete market is comprised of the microsphere and PVA particle sub-segments respectively. Despiute the overall decrease in the market, the microspheres segment is increasing significantly.

The volume of microspheres required per procedure is much higher than the volume of PVA particles required per procedure; 3.5 microspheres are used for every 2 PVA particles required per procedure. The shift towards microspheres has diminished the severity of the drop in unit sales being caused by the declining procedure numbers.

Physicians may prefer the use of microspheres over PVA particles due to peer-reviewed journals that outline how microspheres result in reduced blood loss and higher efficacy in the reduction of fibroids compared to the alternative. PVA particles have been popular in the past due to their affordability and they were previously considered the standard of care.

Scope
2013-2023